$16.99
+0.04 (+0.24%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TBPH is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
46 interventional · 1 observational · 14 with posted results
Held by 12 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, D. E. Shaw & Co., Inc., CITADEL ADVISORS LLC, Qube Research & Technologies Ltd, MARSHALL WACE, LLP, +7 more) · FINRA short interest 7.5 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 3 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System AtrophyNCT05696717Change in OHSA composite score at Week 8 during the double-blind RW periodRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Ampreloxetine, Placebo | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 102 | Jan 2026 | 2025-09-05 |
| Phase 4 COPD and Suboptimal Inspiratory Flow RateNCT05165485results2024-12-20FEV1Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Revefenacin, Tiotropium, Revefenacin Placebo, Tiotropium Placebo | Chronic Obstructive Pulmonary Disease | 404 | 2023-11-13actual | 2024-12-20 |
| Efficacy and Safety of TD-1473 in Crohn's DiseaseNCT03635112results2023-03-13Change From Baseline in Crohn's Disease Activity Index (CDAI) ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was terminated by the sponsor on 16 November 2021 after a planned review by the Independent Data Monitoring Committee. | Drug: Placebo, TD-1473 | Crohn's Disease | 167 | 2021-12-30actual | 2023-03-13 |
| TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental OxygenationNCT05091723AUC0-infNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Nezulcitinib (TD-0903) Dose A, Nezulcitinib (TD-0903) Dose B | Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19) | 14 | 2021-11-24actual | 2021-12-10 |
| Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19NCT04681079observationalViral Load | — | Completed | Drug: albuterol sulfate (MDI), albuterol sulfate (nebulizer) | COVID-19 | 14 | 2021-11-22actual | 2022-01-28 |
| Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureNCT04095793results2022-11-30Number of Participants With Treatment-emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Stopped early due to company decision. Company decision based on analysis results in TD-9855-0169. | Drug: ampreloxetine | Symptomatic Neurogenic Orthostatic Hypotension | 110 | 2021-11-12actual | 2022-11-30 |
| Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureNCT03829657results2023-01-20Proportion of Participants With Treatment Failure at Week 6 of RW Treatment PeriodRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Stopped early due to company decision. Company decision based on analysis results in TD-9855-0169. | Drug: ampreloxetine, Placebo | Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF) | 203 | 2021-11-10actual | 2023-01-20 |
| TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) StudyNCT03920254results2022-11-02Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)Non-randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: Stopped early due to company decision. Company decision based on interim analysis results in TD-1473-0157. | Drug: TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C | Ulcerative Colitis (UC) | 46 | 2021-10-27actual | 2022-11-02 |
| Efficacy & Safety of TD-1473 in Ulcerative ColitisNCT03758443results2022-11-15Change From Baseline in Total Mayo Score (tMS) at Week 8Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: Stopped early due to company decision. Company decision based on interim analysis results in TD-1473-0157. | Drug: TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C, Placebo | Ulcerative Colitis (UC) | 239 | 2021-10-20actual | 2022-11-15 |
| Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855NCT04200573Plasma AUC0-tNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Ampreloxetine | Symptomatic Neurogenic Orthostatic Hypertension, nOH | 31 | 2021-08-19actual | 2021-09-08 |
| Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureNCT03750552results2022-09-14Change From Baseline in Orthostatic Hypotension Symptom Assessment (OHSA) Question #1 Score at Week 4Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: ampreloxetine, Placebo | Symptomatic Neurogenic Orthostatic Hypotension | 195 | 2021-07-21actual | 2022-09-14 |
| TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary FibrosisNCT04589260Part A (SAD) - Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: The Sponsor has decided to stop the study due to business reasons. Study was terminated before initiation of part C and D (Decision to not proceed with Parts C and D was not for safety reasons and do not impact the overall risk benefit of the IMP.) | Drug: TD-1058, Placebo | Idiopathic Pulmonary Fibrosis (IPF) | 72 | 2021-05-06actual | 2022-02-23 |
| TD-0903 for ALI Associated With COVID-19NCT04402866results2022-03-17Part 2: Number of Respiratory Failure-free Days (RFDs) From Randomization to Day 28Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: TD-0903, Placebo | Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19 | 235 | 2021-04-21actual | 2022-03-17 |
| Thorough QT Study to Evaluate Ampreloxetine in Healthy SubjectsNCT04688632QTcFRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Ampreloxetine <Dose A>, Ampreloxetine <Dose B>, Ampreloxetine Placebo, Moxifloxacin, Moxifloxacin Placebo | Symptomatic Neurogenic Orthostatic Hypertension, nOH | 72 | 2021-03-13actual | 2021-04-20 |
| Single Dose Bioavailability and Ethnobridging PK Study in Healthy SubjectsNCT04587713AUC0-tRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: TD-1473 [Tablet A], TD-1473 [Tablet B] | Intestinal Disorder, Bowel Diseases, Inflammatory | 58 | 2020-12-24actual | 2021-04-09 |
| Effect of Inhaled TD-8236 on Allergen-induced Asthmatic ResponseNCT04150341results2022-03-18Area Under the Curve of Change From Baseline in Forced Expiratory Volume (in 1 Second) (FEV1) From 3 to 8 Hours After Inhaled Allergen Challenge at Day 14Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: TD-8236, Placebo | Asthma | 24 | 2020-08-28actual | 2022-03-18 |
| Single and Multiple Ascending Dose Study of TD-8236 by InhalationNCT03652038To assess the safety and tolerability of SAD of TD-8236 by assessing the number, severity and type of treatment emergent adverse eventsRandomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: TD-8236, Placebo | Asthma | 94 | 2020-07-13actual | 2021-09-30 |
| First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19NCT04350736Safety and Tolerability of SAD of TD-0903: Adverse EventsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: TD-0903, Placebo | Acute Lung Injury (ALI) Associated With COVID-19, Inflammatory Lung Conditions Associated With COVID-19 | 54 | 2020-06-24actual | 2021-07-01 |
| Single and Multiple Ascending Dose, First-in- Human Study in Healthy SubjectsNCT04044339To assess the safety and tolerability of SAD of TD-5202 by assessing the number, severity and type of treatment emergent adverse eventsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: TD-5202, Placebo | Healthy | 56 | 2019-11-27actual | 2021-01-14 |
| Multiple Dose Ethnobridging PK Study in Healthy SubjectsNCT03750565Area under the concentration-time curve (AUC0 t)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: TD-1473 - Dose A, TD-1473 - Dose B, TD-1473 - Dose C, Placebo | Inflammatory Bowel Diseases, IBD | 60 | 2019-02-13actual | 2021-01-14 |
| TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)NCT02705755results2022-09-26Part A: Change From Time-matched Placebo in Seated Systolic Blood Pressure (SBP)Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: TD-9855, Placebo | Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease, Hypotension, Orthostatic, Orthostatic Hypotension, Pure Autonomic Failure With Orthostatic Hypotension, Parkinson Disease With Orthostatic Hypotension | 34 | 2018-07-24actual | 2022-09-26 |
| Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging StudyNCT03555617Maximum observed concentration (Cmax) in PlasmaRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: TD-1473, Itraconazole | Inflammatory Bowel Disease | 36 | 2018-07-15actual | 2021-01-14 |
| Drug-Drug Interaction (DDI) Study for TD-9855NCT03432793Change in TD-9855 plasma exposure when administered with itraconazole or fluvoxamineNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: TD-9855, Fluvoxamine, Itraconazole, Caffeine | Drug Drug Interaction (DDI) | 41 | 2018-04-21actual | 2021-01-14 |
| TD-1473 for Active Ulcerative Colitis (UC)NCT02818686Treatment-emergent Adverse Events (TEAE)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: TD-1473, Placebo | Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe | 40 | 2018-03-29actual | 2021-09-30 |
| TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male SubjectsNCT03408470Maximum observed concentration (Cmax) in PlasmaRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: TD-1473 oral capsule, [14C]-TD-1473 IV bolus, [14C]-TD-1473 Oral Capsule | Intestinal Disorders, Bowel Diseases, Inflammatory | 20 | 2018-02-21actual | 2021-01-14 |
| TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)NCT03103412Safety & tolerability of TD-3504 by assessing the number, severity, and type of adverse eventsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: TD-3504, 15N2-tofacitinib, Placebo | Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects | 32 | 2017-11-08actual | 2021-01-14 |
| The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) StudyNCT022675257-day mean GCSI-24H (Gastroparesis Cardinal Symptoms Index) composite scoreRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Velusetrag, Placebo | Gastroparesis | 233 | Jun 2017actual | 2018-04-17 |
| Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly SubjectsNCT02954263The number of adverse events by severity, including changes in vital signs, physical examination, laboratory safety tests, and ECGs.Randomized · Double-masked · Basic science | Phase 1 | Completed | Drug: TD-1439, Placebo | Healthy Adults, Elderly Subjects | 40 | Feb 2017actual | 2021-01-20 |
| Single Ascending Dose Study of TD-1439 in Healthy SubjectsNCT02903095Safety of TD-1439 by assessing the number and severity of adverse events, including changes in vital signs, physical examination, laboratory safety tests, and ECGsRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: TD-1439, Placebo | Healthy Subjects | 66 | Dec 2016actual | 2021-01-19 |
| Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly SubjectsNCT02709928Safety of TD-0714 by assessing the number and severity of adverse events, including changes in vital signs, physical examination, laboratory safety tests, and ECGsRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: TD-0714, Placebo | Healthy Adults, Elderly Subjects | 50 | Nov 2016actual | 2021-01-19 |
| SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy SubjectsNCT02657122To evaluate the safety and tolerability of SAD and MAD of TD-1473 in healthy subjects by assessing the number, severity and type of adverse events, including changes in vital signs, physical examinations, laboratory safety tests and ECGsRandomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: TD-1473 for SAD, Placebo for SAD, TD-1473 for MAD, Placebo for MAD | Healthy | 72 | Apr 2016actual | 2021-01-19 |
| A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy SubjectsNCT02663089AUC(0 inf) of total drug-related material (radioactivity) in plasma after a single IV microtracer of [14C] GSK961081 (concomitant with an inhaled non-radiolabelled dose) and a single oral dose of [14C] GSK961081Open-label · Treatment | Phase 1 | Completed | Drug: [14C]-GSK961081 solution for IV infusion, [14C]-GSK961081 oral solution, GSK961081 dry powder for inhalation | Pulmonary Disease, Chronic Obstructive | 6 | 2016-03-17actual | 2021-10-06 |
| Single Ascending Dose Study of TD-0714 in Healthy SubjectsNCT02639078Safety and tolerability of TD-0714 by assessing the number, severity and type of adverse events, including changes in vital signs, physical and neurological examinations, laboratory safety tests and ECGsRandomized · Double-masked · Basic science | Phase 1 | Completed | Drug: TD-0714, Placebo Comparator | Healthy | 56 | Feb 2016actual | 2021-10-13 |
| TD-6450 MAD Study in HCV Infected SubjectsNCT02116543Adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: TD-6450, Placebo | Hepatitis C, HCV | 47 | Oct 2014actual | 2021-01-19 |
| TD-6450 SAD and MAD in Healthy SubjectsNCT02022306Adverse eventsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: TD-6450, Placebo | Hepatitis C | 111 | Aug 2014actual | 2021-01-14 |
| TD-1607 MAD Study in Healthy SubjectsNCT01949103Number of adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: TD-1607, Placebo | Infections, Bacterial Infections | 48 | Jun 2014actual | 2021-01-19 |
| Phase 2 Study of TD-9855 to Treat FibromyalgiaNCT01693692results2022-03-04Percentage Change in Pain Score Based on the Mean of the Last 7 Daily Pain Numeric Rating Scale (NRS) Scores From the Daily Pain DiariesRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: TD-9855 Group 1, TD-9855 Group 2, Placebo | Fibromyalgia | 392 | Jan 2014actual | 2022-03-04 |
| Phase 2 Study of Velusetrag in Diabetic or Idiopathic GastroparesisNCT01718938Gastric emptying half time (GE t1/2)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: velusetrag dose 1, velusetrag dose 2, velusetrag dose 3, placebo | Gastroparesis | 34 | Dec 2013actual | 2018-02-26 |
| TD-9855 Mass Balance StudyNCT01924143To define the routes and rates of elimination and mass balance of [14C]-labeled TD-9855Open-label · Treatment | Phase 1 | Completed | Drug: TD-9855 | ADHD, Fibromyalgia | 6 | Nov 2013actual | 2021-01-19 |
| A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)NCT01458340results2022-03-14Change From Baseline in AISRS Total Score at Day 42Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: TD-9855, TD-9855, Placebo | Attention-Deficit/Hyperactivity Disorder, ADHD | 295 | Oct 2013actual | 2022-04-04 |
| TD-1607 SAD Study in Healthy SubjectsNCT01791049Safety and tolerabilityRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: TD-1607, Placebo | Serious Infections Due to Known or Suspected Gram-positive Pathogens | 64 | Aug 2013actual | 2021-01-19 |
| A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy SubjectsNCT01644240results2017-08-02CmaxRandomized · Triple-masked · Other | Phase 1 | Terminatedsponsor's stated reason: For business reasons | Drug: TD-8954, Placebo - saline | Gastrointestinal Motility Disorder | 16 | Nov 2012actual | 2017-08-02 |
| An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.NCT00674817results2017-03-27Maximal Change in Forced Expiratory Volume in One Second (FEV1) From Baseline (Pre-dose on Day 1) in Combination With Short Acting Bronchodialator (Salbutamol or Ipratropium Bromide) at 1h,12h and 24h.Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: 400 microgrammes GSK961081, 1200 microgrammes GSK961081 | Pulmonary Disease, Chronic Obstructive | 45 | 2008-10-01actual | 2021-10-20 |
| A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy VolunteersNCT00687700To assess the bronchodilation of single doses of GSK961081 over 24 hours following ß blockade with the ß antagonist propranolol as measured by sGaw in healthy subjects.Randomized · Treatment | Phase 1 | Completed | Drug: GSK961081, GSK961081 matching placebo, Propranolol, Propranolol matching placebo | Pulmonary Disease, Chronic Obstructive | 23 | 2008-05-27actual | 2021-10-06 |
| Succinate Salt Version of GSK961081 for Healthy VolunteersNCT00550225FEV1 at intervalsRandomized · Treatment | Phase 1 | Completed | Drug: GSK961081, GSK961081 matching placebo | Pulmonary Disease, Chronic Obstructive | 18 | 2008-01-08actual | 2021-10-06 |
| TD-1792 in Gram-positive Complicated Skin and Skin Structure InfectionNCT00442832Clinical responseRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: TD-1792, Vancomycin | Staphylococcal Skin Infection | 203 | May 2007actual | 2021-01-20 |
| Study of GSK961081 in Healthy Volunteer SubjectsNCT00887406General safety and tolerability (adverse events, clinical laboratory safety tests, cardiac monitoring, vital signs (including postural changes in blood pressure), 12-lead ECG parameters including QTc(b) and QTc(f), blood glucose and serum potassium).Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: GSK961081 15mcg SD, GSK961081 3mcg SD, GSK961081 50mcg SD, Placebo SD, GSK961081 100mcg SD, GSK961081 200mcg SD, GSK961081 300mcg SD, GSK961081 100mcg RD, GSK961081 300mcg RD, Placebo RD | Pulmonary Disease, Chronic Obstructive | 46 | 2006-10-04actual | 2021-10-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19